CSL Ltd Annual Report 2019

Christine O’Reilly BBUS Age 58 Independent Non- executive Director Ms Christine O’Reilly has been a Director of CSL Limited since February 2011. Ms O’Reilly has non-executive experience in a number of sectors including infrastructure, property, private health insurance, energy and medical research. She also has deep strategic and operational leadership experience, with a focus on corporate transformational change, debt and equity capital markets and merger & acquisitions. Ms O’Reilly was the Co-Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management from July 2007 until September 2012. Prior to this, she was the Chief Executive Officer of the GasNet Australia Group. Ms O’Reilly’s early work history includes participating in the reform and establishment of the regulatory framework for the Australian gas industry, eight years with the investment bank, Centaurus Corporate Advisory Services, and audit experience with Price Waterhouse where she qualified as a chartered accountant. Other directorships and offices (current and recent): –– Director of Transurban Group (since April 2012); –– Director of Medibank Private Limited (since March 2014); –– Director of Stockland Limited (since August 2018); –– Director of Baker Heart and Diabetes Institute (since July 2013); and –– Former Director at Energy Australia Holdings Limited (from September 2012 to August 2018). Board Committee membership: –– Chairman of the Corporate Governance and Nomination Committee. –– Member of the Audit and Risk Management Committee. –– Member of the Human Resources and Remuneration Committee. Tadataka “Tachi” Yamada KBE MD, BA Age 74 Independent Non- executive Director Dr Tadataka Yamada has been a Director of CSL Limited since September 2016. Dr Yamada has broad and extensive experience with global corporate and not-for profit organisations in the pharmaceutical and medical sector. He has a deep understanding of medical technologies, research and development and provides strategic global insight to understanding the health access issues and the changing external environment. Prior to this, he was the Chief Medical and Scientific Officer at Takeda Pharmaceuticals, as well as a Member of the Board. He has also held the role of President on the Bill & Melinda Gates Foundation Global Health Program and prior to that was Chairman of Research and Development at GlaxoSmithKline. Dr Yamada has received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire. Other directorships and offices (current and recent): –– Director of Agilent Technologies Inc. (since March 2011); –– Chairman of Clinton Health Access Initiative (since March 2017); and –– Venture Partner at Frazier Healthcare (since June 2015). Board Committee membership: –– Member of the Innovation and Development Committee. Fiona Mead LLB (Hons), BComm Age 50 Company Secretary and Head of Corporate Governance Ms Mead was appointed Company Secretary and Head of Corporate Governance effective June 2018. Previously, she was the Company Secretary and a member of the Executive Leadership Team at Tabcorp Holdings Limited. Prior to that, Ms Mead was the Company Secretary at Asciano Limited, and earlier, Assistant Company Secretary at Telstra. Fiona began her career as a lawyer with law firm Ashurst. Ms Mead is a fellow of the Governance Institute of Australia and a Graduate member of the Australian Institute of Company Directors. She is also the Chairman of St Michael’s Grammar School. Board committees The Board has established a number of standing committees as a mechanism for considering detailed issues and, where appropriate, making recommendations for consideration by the Board. These committees have charters setting out matters relevant to the composition, responsibilities and membership of each committee. More on CSL.com (Our Company > Board and Management) CSL Limited Annual Report 2019 45